Aclaris Therapeutics ACRS
NASDAQ ACRS
$5.28 -0.15 (-2.76%)
At close: Sep 29, 2026 · 4:00 PM EDT

Aclaris Therapeutics (ACRS) Cash from Restructuring (2016)

Updated

Aclaris Therapeutics' Cash from Restructuring came in at $2.78 million for FY2016.

Analysis

Aclaris Therapeutics (ACRS) Cash from Restructuring (2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Aclaris Therapeutics 759.25 Mn 759.25 Mn 1.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 2.78 Mn
API Access

Aclaris Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=ACRS&period=max&api_key=YOUR_API_KEY